Actinium Pharmaceutical's Announces Analyst Coverage
BURTON, Mich., Dec. 3, 2013 /PRNewswire/-- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) a pharmaceutical company developing drugs for treatment of cancer with intent to cure or significantly improve survival of the affected patients announces analyst coverage. Actinium's drugs are monoclonal antibodies labeled with radioisotopes. The push by large pharmaceuticals companies to acquire smaller biotech businesses to gain new drugs that could bolster income is focusing increasingly on cancer therapy. Actinium has recently been the subject of a well respected analyst research coverage. This report sheds light on Actinium's current progress and future potential. Read this full report here: http://smallcaptraders.com/is-antm-an-acquisition-target-for-global-pharmaceutical-companies/
SOURCE Actinium Pharmaceuticals, Inc.
More by this Source
With Bone Marrow Transplants Rising, New Therapy Gives Hope to Those Over 55
Jan 08, 2014, 09:40 ET
Four Things to Ask Your Doctor About Bone Marrow Transplants
Dec 20, 2013, 08:35 ET
Actinium Pharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference
Dec 09, 2013, 16:05 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.